Sanofi Makes Case For Frontline Use Of Myeloma Drug Sarclisa
Promising Data In Newly Diagnosed Transplant-Eligible Patients
Sarclisa, Sanofi's first in-house cancer drug to be approved since 2010, is making slow if steady progress on the sales front but remains way behind J&J's multiple myeloma behemoth Darzalex. Still, the company has been touting its case to be the anti-CD38 of choice at the ASH meeting.
